Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01303705
Other study ID # PH&S IRB 10-088
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 14, 2010
Est. completion date July 5, 2016

Study information

Verified date August 2018
Source Providence Health & Services
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial will examine a novel combination of anti-OX40 to induce proliferation of memory and effector T cells in conjunction with cyclophosphamide (CTX) and radiation to induce tumor antigen release with the overall goal of promoting an immune response against prostate cancer.


Description:

A Phase Ib trial design will be employed in patients with metastatic PC who have failed prior androgen ablation and docetaxel. CTX will be administered also on Day 1. All patients will receive RT (800 cGy in a single fraction) to up to 3 bone metastatic sites on Day 4 in the AM. Anti-OX40 at 0.4 mg/kg IV will be given on days 4, 6 and 8. The timing of CTX, RT and anti-OX40 are based on the pre-clinical models and the observation that the synergies of CTX and RT are reduced when they are given more than one week after anti-OX40 and are maximized when given within 3 days of starting anti-OX40. The proposed radiation dose is commonly used to palliate bone pain in PC and generally will not induce significant cytopenias. The CTX dose will be escalated in successive cohorts of 3 - 6 patients to assure patient safety. The dose levels of CTX will be 300, 600 and 900 mg/m2 intravenously in the initial stage of the study. The range of CTX doses is commonly used in general oncology practice and is not expected to induce prolonged myelosuppression, although transient cytopenias are likely. Concurrent CTX and RT has been well-tolerated at much higher dose-intensities than the investigators are proposing (52-54), thus the investigators are not expecting significant adverse events from the combination before anti-OX40. As a safety consideration, the investigators are not giving CTX and RT on the same day as a high proportion of men with prostate cancer have bone metastases in the pelvis. RT to the pelvis could cause radiation cystitis that would be exacerbated by the metabolites of CTX (e.g., acrolein) that can accumulate in the bladder in the 24-36 hours after administration. After the dose-escalation portion of the trial then up to 20 additional patients can enroll in the study at the maximum tolerated CTX dose if clinical responses are seen, for a maximum total of 37 patients using a Simon two-stage design (see Section 10 for details).

The main clinical objective of the trial will be to characterize toxicity and estimate the response rate of the combination of anti-OX40, CTX and RT. Both radiographic and PSA responses will be followed. RECIST will be used for radiographic assessment and a significant PSA response will be defined as a 50% or greater decrease from baseline measured at 3 and 6 weeks after the start of treatment based on the PCWG2 guidelines (55).

Patients will enroll consecutively to each cohort assuming no dose-limiting toxicities. Three patients will be treated per cohort and if there are no dose-limiting toxicities, then enrollment to the next cohort can begin. If a dose-limiting toxicity is encountered in the first three patients in any cohort, then an additional three patients will be enrolled in that cohort.* This dosing strategy will allow for a three-fold escalation of CTX.

The main hypothesis of this study is that CTX and RT will induce tumor breakdown providing a source of antigen for self-vaccination and anti-OX40 will amplify CD8-mediated effector responses across a broad spectrum of prostate cancer antigens resulting in further regression of prostate cancer. The investigators predict that anti-OX40 will not increase circulating or intratumoral Treg, and this should help to further augment immune responses.

*For the dose escalation portion of the study, the first 2 patients in any cohort can be treated on consecutive weeks. If there are no Dose Limiting Toxicities, then the third patient can begin treatment 28 days after the second patient has completed anti-OX40. If the third patient has no DLT, then the next cohort can open 28 days after the third patient has completed anti-OX40. If a DLT occurs with patient 3 in any cohort, then up to 3 more patients will enroll to the same cohort at a frequency of one patient every 28 days after the previous patient has completed anti-OX40 assuming no DLT.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date July 5, 2016
Est. primary completion date July 5, 2016
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patients with measurable or evaluable metastatic adenocarcinoma of the prostate. Either histologic or cytologic diagnosis is acceptable

2. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 (Appendix A.)

3. Age 18 years old or above

4. Laboratory values (performed within 28 days prior to enrollment) as follows:

- WBC = 2000/microlitre

- Serum creatinine < 1.5 X upper limit of laboratory normal

- Hgb > 8g/dl (patients may be transfused to reach this level)

- Platelets > 100,000 cells/mm3

- Total bilirubin < 1.5 X upper limit of laboratory normal, unless due to Gilbert's disease

- AST (SGOT) and ALT (SGPT) < 2.5 X upper limit of laboratory normal

- Alkaline phosphatase < 2.5 X upper limit of laboratory normal (If alkaline phosphatase > 2.5 X upper limit of laboratory normal due to bone metastases, then patient is eligible.)

- HIV 1 and 2 antibody Negative

- Hepatitis B surface antigen Negative

- Hepatitis C antibody Negative

- PSA > 2 ng/ml

- Testosterone < 50 ng/ml

5. Confirmed radiographic and/or PSA progression (using PCWG2 definitions) after at least one androgen ablation regimen and docetaxel.Patients who refuse docetaxel chemotherapy or who are not candidates for docetaxel are eligible to enroll.

6. At least one bone metastatic lesion amenable to radiation

7. Ability to give informed consent and comply with the protocol. Patients with a history of psychiatric illness must be judged able to understand the investigational nature of the study and the risks associated with the therapy

8. No active bleeding

9. No clinical coagulopathy (INR < 1.5, PT < 16 seconds, PTT < 38 seconds)

10. Anticipated lifespan greater than 12 weeks

11. Patients on LHRH agonists or bisphosphonates prior to study enrollment should continue these medications without change

Exclusion Criteria:

1. Active infection.

2. Active autoimmune disease.

3. Previous treatment with mouse monoclonal antibodies

4. Need for chronic maintenance oral steroids.

5. Active brain metastatic disease. Patients with treated brain metastases with surgery, gamma-knife radiosurgery or radiation and stable for at least 4 weeks and off steroids are eligible.

6. Any medical or psychiatric condition that in the opinion of the PI would preclude compliance with study procedures.

Study Design


Intervention

Drug:
Anti-OX40
Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8 of the study. The total anti-OX40 dose will be reconstituted in 100 ml 0.9% saline and infused over no more than 60 minutes intravenously. A single-use non-pyrogenic durapore membrane low protein binding filter (e.g.: Braun 1.2 micron air eliminating filter or equivalent) shall be used to filter the study product in the line between infusion bag and patient.
Radiation:
Radiation
8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment. Imaging such as bone scan, MRI, CT scan, or radiograph must identify the target lesion as consistent with metastatic disease. Any bone lesion that is inducing pain or where there may be a clinical concern for potential pathological fracture will be selected over asymptomatic lesions.
Drug:
Cyclophosphamide
CTX will be administered on day 1 (Friday only) at a dose determined by cohort assignment. The drug should be diluted per institutional standards. An added dose of IV fluids may help prevent bladder toxicity. In this protocol, CTX will be administered intravenously over 30 - 60 minutes.

Locations

Country Name City State
United States Providence Portland Medical Center Portland Oregon

Sponsors (2)

Lead Sponsor Collaborator
Providence Health & Services MedImmune LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose The primary objective of this trial is to determine the maximum tolerated dose (within the range expected to induce anti-tumor and immunological effects) of CTX administered in combination with radiation and anti-OX40 in men with metastatic castrate- and chemotherapy-resistant prostate cancer. The MTD will be assessed according to the dose escalation schema (timeframe is not specific for MTD assessment - it is based on enrollment)*
Secondary Immune and Clinical Responses Secondary objectives are as follows:
Determine the effect of anti-OX40, CTX and radiation on circulating numbers and phenotypes of CD4 and CD8 T cells.
Measure the proliferation and activity of effector and memory T cells after CTX, radiation and anti-OX40.
Perform exploratory studies of cellular and humoral immune responses against prostate cancer cell lines.
Estimate the response rate of the regimen that includes the highest dose of CTX determined to be safe.
Days 11, 18, 25 and 39
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A